Drug Profile
NLX 101
Alternative Names: F15599; NLX-101Latest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer Neurolixis
- Class Antidementias; Antidepressants; Antipsychotics; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Fragile X syndrome; Rett syndrome
- Preclinical Depressive disorders
- Discontinued Cognition disorders; Mood disorders; Schizophrenia